expanding portfolio miDiagnostics is actively developing an extensive portfolio of tests for screening, diagnosis and monitoring across a wide range of health conditions, including infectious diseases, signaling opportunities to cross-sell integrated chip-based testing solutions to labs, clinics and hospital networks seeking comprehensive diagnostic capabilities.

tech leadership The company leverages silicon chip technology, nanofluidic processing on a chip, and a compact reader, enabling lab-quality tests with built-in connectivity, presenting a compelling value proposition for customers seeking rapid, connected diagnostics and potential deployment in point-of-care settings.

strategic partners With imec origins and a Johns Hopkins collaboration, miDiagnostics has strong research credibility and potential for co-development, licensing, or strategic partnerships that can open doors to large health systems and research institutions seeking innovative diagnostic platforms.

market momentum Recent recognitions and awards, including the Exemplary Woman of Achievement for the CEO and finalist status for Medtech of the Year, indicate growing brand visibility and validation that can be leveraged in outreach to investors, customers, and partners interested in high-potential medical technology vendors.

growth readiness Funding of thirty-two million and a lean employee base position miDiagnostics for scalable deployment; sales approaches can target mid to large healthcare providers, contract manufacturers, and regional distributors looking to integrate next-gen diagnostics with scalable connectivity and data integration.